Anti-transforming growth factor beta as a treatment for laryngotracheal stenosis in a canine model.
Laryngoscope
; 118(3): 546-51, 2008 Mar.
Article
en En
| MEDLINE
| ID: mdl-18176351
ABSTRACT
OBJECTIVES/HYPOTHESIS:
Laryngotracheal stenosis (LTS) represents a significant treatment dilemma faced by otolaryngologists. Recent topical use of Mitomycin C as an adjunctive treatment has proved helpful but does not completely prevent stenosis. Current literature suggests that transforming growth factor beta (TGFB) plays a significant role in the development of subglottic stenosis. We modified an existing canine model to test antitransforming growth factor beta (anti-TGFB) as a possible treatment for laryngotracheal stenosis. STUDYDESIGN:
Pilot study in a modified canine model.METHODS:
Eight mixed-breed dogs underwent cautery injury to the subglottic region creating subsequent laryngotracheal stenosis. Four dogs were treated with saline injection into the injury site and four dogs were treated with a combination of intravenous (5 mg/kg on day 0 and 5 of the experiment) and local injection of anti-TGFB (50 micrograms).RESULTS:
In the canine model of induced subglottic airway injury, a combination of intralesional and intravenous anti-TGFB results in a reduction in tracheal stenosis (P < .05) and an increase in survival time (P < .03) when compared to the saline control subjects.CONCLUSIONS:
Anti-TGFB appears to be a useful adjunct in the treatment of LTS. Further study regarding the optimal dosing, route of administration, and timing of delivery is needed to understand the role of anti-TGFB in the treatment for laryngotracheal stenosis.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Estenosis Traqueal
/
Laringoestenosis
/
Factor de Crecimiento Transformador beta
/
Anticuerpos
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
Laryngoscope
Asunto de la revista:
OTORRINOLARINGOLOGIA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Estados Unidos